t.m.t.m.8432

[marutsubame @marutsubame3]

最高の仕上がりになった 信州の天空の道をみて

[Hidehito HORINOUCHI @HHorinouchi]

🆙#WCLC26 #LCSM Oral Session
🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC
🎙️ @MartinReck2
🔢OA04.02
🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort
☑️NCT05925530
🔗 https://t.co/rN1vqVmvgD
@OncoAlert @Larvol @IASLC

[Isabelle Opitz @IsaOpitz]

🫁 New AATS Expert Consensus Document on N2+ NSCLC

It was a pleasure and great learning to contribute to the 2026 @AATSHQ Expert Consensus Document on the evaluation and management of N2+ non-small cell lung cancer (NSCLC) under the leadership of Philip Linden and Thomas D'Amico.

The management of N2-positive NSCLC remains one of the most complex areas in thoracic oncology!

This new consensus document provides updated recommendations on staging, patient selection and treatment strategies, highlighting the importance of multidisciplinary decision-making and close collaboration across specialties. 🤝🫁

Many thanks to the @AATSHQ and all colleagues involved in this collaborative effort.

Link to the paper: https://t.co/bDH4ruttRK

#ThoracicSurgery #LungCancer #NSCLC #SurgicalOncology #MultimodalTherapy #AATS

[Hidehito HORINOUCHI @HHorinouchi]

🔥SAFFRON: "Statistically significant and clinically meaningful PFS & OS improvement"
🆙 @AstraZeneca
👥Patients: EGFRm, MET overexpression or amplification, progressed osimertinib
3⃣Phase III
⚖️Osimertinib + Savolitinib
⚖️Platinum doublet
🔢NCT05261399
🔗 https://t.co/zrIw3rngAw
#LCSM @OncoAlert @Larvol @EGFRResisters

[Drew Moghanaki @DrewMoghanaki]

NEW: An update on the harmful consequences of neoadjuvant chemoimmunotherapy in poorly selected pts with stage III NSCLC. @JTOonline #WCLC26 https://t.co/N9GVbMzONK

[Erman Akkus @Erman_Akkus]

Baseline IL-6 independently predicts severe immune-related toxicity and poor survival in advanced gastric cancer treated with immunotherapy | Gastric Cancer | Springer Nature Link https://t.co/ULABtjsJys

[ライブドアニュース @livedoornews]

【憤り】崩れた自宅の前でピースした姿に、写真をAIで加工された男性「本当に残念。悔しい」
https://t.co/TYOv8mR5Kn

新聞社の取材を受けた時に撮影された画像が加工されたとみられる。元の写真を撮影した毎日新聞は、｢極めて遺憾と考えており、法的措置も視野に対応を検討しています｣とコメント。

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 BTC, RWE 1L CisGem + durva (N=1358)
⚠️ 33% TOPAZ-1–ineligible
📈 mOS: 16.1 vs 12.5 mo
⏳ mPFS: 8.2 vs 6.5 mo
🛡️ No excess toxicity in TOPAZ-1–out pts

💡 Activity appears broadly maintained beyond trial eligibility criteria

🔗 https://t.co/H2fldEz20l
@OncoAlert

[Hidehito HORINOUCHI @HHorinouchi]

🔥CheckMate 77T: Biomarkers of nivolumab benefit in resectable NSCLC
🆙 @Nature
🎯ctDNA clearance before surgery: 66% (nivo) vs 38% (placebo); 50% of clearance pts achieved pCR with nivo
🎯KEAP1/STK11/CDKN2A/SMARCA4 alterations: EFS prolonged with nivo (HR 0.48) despite historically poor prognosis
🎙Dr. Tina Cascone @MARIANOPROVENCI
#LCSM @OncoAlert @Larvol
https://t.co/b5qYobnaCs

[io302 @io302]

電車内の女性達の話

『母親、妹に子宮頸がんワクチンするなってスピってるんだけど』
『反ワクじゃん、あんた接種したの？』

『怖いよね〜って嘘ついて接種した、バレるとヒスるから』
『AI教えてあげればw』

マックの女子高生じゃないけど、リアルで『反ワク』って聞くとは思わなかったなw

[Dr. KID @Dr_KID_]

佐賀市で、4歳男児が公園で遊んでいた際に熱中症の疑いで救急搬送された。遊んでいた時間はわずか5分ほどだったが、のどの痛みや倦怠感を訴え、中等症と診断された。命に別状はないという。短時間の屋外活動でも子どもは、暑い時間帯の外遊びには注意が必要となる。
https://t.co/AsKhKnKSEm

[Stephen V Liu, MD @StephenVLiu]

Nature publication today from Dr. Tina Cascone et al with tremendous detail on biomarkers from CheckMate 77T predicting benefit from perioperative nivolumab in patients with resectable NSCLC. Amazing amount of detailed data in this @Nature paper.

https://t.co/Sb0H4YOpxz

[Jarushka Naidoo @DrJNaidoo]

Biomarkers of periop nivolumab in NSCLC @Nature

- CM77T: nivo=98 pbo=92
- preop ctDNA clearance= Nivo 66% v PBO 38% assoc w pCR
- ctDNAcl+pCR=⬆️EFS v no pCR HR 0.29
- KEAP1/STK11/CDKN2A/SMARCA4 =⬆️PFS HR 0.48

Congrats #TinaCascone @marianoprovenci #LCSM https://t.co/10kQD12Jir

[Hidehito HORINOUCHI @HHorinouchi]

🔥From RAS inhibitor resistance to rational combination strategies
🆙 @NatureMedicine
🎯RAS(ON) inhibitor doublet (daraxonrasib + zoldonrasib) & RTK-targeting biologics (T-DXd, amivantamab) are key combination strategies
🎙Dr. Paula Lynch @graokane
@OncoAlert @Larvol @KRASKickers
https://t.co/HuVQKbqIP8

[Lung Cancer Europe @LungCancerEu]

#LungCancer can develop genetic changes during treatment. ctDNA may help us detect some of those changes through a blood test.

A new JAMA review looks at liquid biopsy for treatment selection, response, resistance and recurrence.

https://t.co/QQtpqRsXEo

#LCSM

[Vivek Subbiah, MD @VivekSubbiah]

💫Very comprehensive
Review on intratumor heterogeneity @NatureCancer by @Jonathancmwan, @NickyMcGranahan and the one & only @CharlesSwanton @OncoAlert
https://t.co/iTCUw3XZ70

[Lung Cancer Europe @LungCancerEu]

‼️ A tumour isn’t necessarily the same all the way through.

Different populations of cancer cells can exist within it and evolve over time, including under the pressure of treatment.

A new Nature Cancer review looks at how understanding and tracking that evolution could lead to better ways to diagnose, monitor and treat cancer.

#LungCancer research has been central to building that understanding. #LCSM

https://t.co/SiV3LbBDLA

[ア ルミン @cheche_xyz]

冨安きたぁぁぁぁぁぁ！！！
パレスのセンスの高さよ笑

[Kiha-NN40 @Kiha_NN40]

落石、感動···
花咲線素晴らしい···

[Dr. KID @Dr_KID_]

乳幼児突然死症候群（SIDS）から赤ちゃんを守るため、安全な睡眠環境を整えましょう。
お昼寝でも必ず「仰向け」で寝かせ、体が沈み込まない「硬く平らなマットレス」を使用します。窒息を招くため、寝床には枕や毛布など柔らかいものを置かず、添い寝も避けてください。受動喫煙を避けることも重要。